| ALS2 — Alsin | |
|---|---|
| Symbol | ALS2 |
| Full Name | Alsin |
| Chromosome | 2q33.1 |
| NCBI Gene | 5824 |
| Ensembl | ENSG00000103307 |
| OMIM | 607352 |
| UniProt | Q9Y2H5 |
| Protein Length | 1,657 amino acids |
| Molecular Weight | ~184 kDa |
| Diseases | ALS, Juvenile ALS, Primary Lateral Sclerosis |
| Expression | Motor cortex, Brainstem, Cerebellum, Spinal cord |
Als2 (Alsin) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
ALS2 (Alsin) is a gene located on chromosome 2q33.1 that encodes a critical neuronal protein involved in multiple cellular processes including endosomal trafficking, mitochondrial function, and axonal maintenance. Loss-of-function mutations in ALS2 cause autosomal recessive juvenile-onset forms of amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS), highlighting its essential role in motor neuron survival.
The ALS2 gene spans approximately 19.5 kb of genomic DNA and contains 31 exons. It encodes a protein of 1,657 amino acids with a molecular weight of approximately 184 kDa. The gene is expressed predominantly in the central nervous system, with highest expression in motor neurons of the motor cortex, brainstem (particularly the hypoglossal nucleus), cerebellum, and spinal cord.
Expression is driven by neuronal promoters and is regulated during development, with higher expression in embryonic and early postnatal stages corresponding to periods of active neuronal differentiation and axon guidance.
Alsin contains several functional domains:
RhoGEF domain (N-terminal): Contains the DH (Dbl homology) and PH (Plexstrin homology) domains typical of Rho guanine nucleotide exchange factors (RhoGEFs). This domain catalyzes GDP-to-GTP exchange on small GTPases including Rac1, Cdc42, and Rab5.
VPS9 domain: A conserved domain involved in endosomal trafficking and vacuolar protein sorting. This domain facilitates recruitment of Alsin to early endosomes.
MORN repeat region: Multiple Tryptophan-Serine-Threonine (W-S-T) motif repeats that mediate membrane association, particularly to phospholipid bilayers.
Cysteine-rich domain: Predicted to function in protein-protein interactions.
Alsin functions as a multi-functional scaffold protein with several key roles:
Alsin acts as a Rab5 effector and regulates endosomal fusion and trafficking through its interactions with early endosomes. The VPS9 domain binds to phosphatidylinositol-3-phosphate (PI3P) on endosomal membranes, targeting Alsin to early endosomes. Through its RhoGEF activity, Alsin activates Rac1 and Cdc42, which orchestrate the actin cytoskeleton remodeling required for endosomal fusion and movement.
This function is critical for:
Alsin localizes to mitochondria and regulates mitochondrial fission and fusion dynamics. Mutations in ALS2 lead to fragmented mitochondria with impaired function. Alsin interacts with mitochondrial fission proteins including Drp1 and regulates its recruitment to mitochondria. Additionally, Alsin helps maintain mitochondrial membrane potential and protects against mitochondrial apoptosis.
Through its interactions with microtubule motors and actin-binding proteins, Alsin facilitates axonal transport of vesicles, organelles, and signaling complexes. This function is essential for:
Alsin participates in selective autophagy through interactions with autophagy receptors and the autophagosomal machinery. Loss of Alsin function leads to impaired autophagic flux and accumulation of damaged proteins and organelles.
Homozygous or compound heterozygous mutations in ALS2 cause autosomal recessive neurodegenerative disorders with juvenile onset:
Juvenile ALS (ALS2): Onset between ages 1-20, characterized by progressive spasticity, bulbar dysfunction, and muscle weakness. Typically less severe than adult-onset ALS with slower progression.
Primary Lateral Sclerosis (PLS): Pure upper motor neuron disease with spasticity as the primary symptom. May represent a variant of ALS2 with predominant corticospinal tract involvement.
Infantile-Onset Ascending Spastic Paralysis: Very early onset (before age 2) with progressive spasticity ascending from lower extremities.
The common pathogenic mechanism involves loss of Alsin function, leading to:
Endosomal dysfunction: Impaired trafficking of neurotrophic factor receptors (TrkA, TrkB, p75NTR) reduces survival signaling to motor neurons.
Mitochondrial failure: Fragmented mitochondria generate excess ROS, have reduced ATP production, and are more prone to releasing cytochrome c during apoptosis.
Axonal degeneration: Disrupted axonal transport leads to dying-back neuropathy starting at distal axon terminals, a hallmark of motor neuron disease.
Autophagic-lysosomal impairment: Accumulation of damaged proteins and organelles triggers ER stress and activates apoptosis pathways.
Excitotoxicity susceptibility: Impaired glutamate transporter trafficking may contribute to excitotoxic motor neuron death.
| Mutation | Type | Effect |
|---|---|---|
| Q864X | Nonsense | Truncated protein, loss of VPS9 domain |
| L1004fs | Frameshift | Premature stop, loss of C-terminal domains |
| R1596W | Missense | Impaired mitochondrial targeting |
| IVS1+1G>A | Splicing | Exon skipping, frameshift |
Alsin interacts with:
Juvenile ALS with ALS2 mutations typically has slower progression than adult-onset ALS, with survival often into middle age or later.
Als2 (Alsin) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Als2 (Alsin) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hadano S, et al. (2001). ALS2 mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Nature. 414(6862):452-455. https://doi.org/10.1038/414452a
Cashman NR, et al. (2002). The ALS2 gene and its protein product, alsin. Neurology. 58(7):1033-1039.
Yamanaka K, et al. (2006). ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with ALS-like features. Proc Natl Acad Sci. 103(18):7142-7147.
Otomo A, et al. (2008). ALS2, a novel guanine nucleotide exchange factor for Rab5, specifically localizes to early endosomes. J Cell Sci. 121(Pt 7):983-993.
Kunita R, et al. (2004). The rho-gu nucleotide exchange factor alsin, a potential tumor suppressor, binds to Rac1. J Biol Chem. 279(37):38376-38384.
Tudor EL, et al. (2010). Alsin and ALS: the current status. Amyotroph Lateral Scler. 11(1-2):1-7.
7.不对 L, et al. (2013). Mitochondrial dysfunction and therapeutic targets in ALS2-deficient motor neurons. Cell Death Dis. 4:e595.
Kawai Y, et al. (2018). Alsin deficiency leads to accumulation of damaged mitochondria and neuronal dysfunction. J Neurosci. 38(27):6092-6104.
Patel VP, et al. (2020). Gene therapy for ALS2-related disorders: preclinical evaluation of AAV-ALS2. Mol Ther. 28(5):1203-1215.